Business Wire

KAYRROS

31.3.2020 08:07:10 CEST | Business Wire | Press release

Share
Kayrros and Copernicus Images Allow Quantification of Global Methane Leaks Equivalent to 1.8 Gigatons of CO² Emissions

Kayrros SAS, a leading global asset observation platform, is today announcing the latest findings from its technology to track, quantify and attribute global methane emissions. Kayrros uses data from the European Space Agency (ESA) Copernicus program’s Sentinel-5 Precursor satellite and has built a detection and quantification model to trace emissions back to their source. These unique and comprehensive findings show that:

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200330005801/en/

  • Methane emissions can now be detected and quantified at an asset level on a global scale , which represents a major step-change in the ability to work towards the reduction of man-made emissions.
  • The data shows that there are around 100 high volume-emitting events at any one time around the world. Together, in the course of one year, they are releasing 20 megatons of methane which is equivalent to 1.8 gigatons of CO2 in the first twenty years .1
  • Through its proprietary attribution model, Kayrros can identify that around one half of that CO2 equivalent in the first twenty years, or 1 gigaton, are in regions with heavy industry such as oil & gas, coal mining, etc . This is equivalent to the total annual CO2 emissions of Germany and France together.2

Kayrros is a leading Earth observation analytics player able to combine extensive mapping of assets, deep sectoral understanding, and complex machine learning algorithms as well as detection and quantification models in order to identify the missing link between concentrations and emissions.

“What we are announcing today is ground-breaking,” says Antoine Rostand, CEO of Kayrros. “The combination of Sentinel 5-P satellite imagery and Kayrros technology represents a world first in the ability to track and attribute these substantial individual methane leaks. The good news is most of these are man-made and can easily be addressed through action by individual companies, governments and regulators.”

Claus Zehner, Sentinel 5-P Mission manager at ESA, says, “We are pleased to support Kayrros in its use of the Sentinel 5-P data to develop new tools for global methane emissions monitoring. Europe’s investment into satellite technology is ever more crucial if it can support the reduction of global emissions and slow down climate change.”

Kayrros has presented its methodology and approach to the European Commission and its Directorate General for Energy. The upcoming European strategy to reduce methane emissions will include a methodology for methane measurement and quantification that builds on Copernicus and other satellite data for detection and validation. Kayrros remains in dialogue with the European Commission about its work.

Kayrros has also worked with LSCE 3 scientists on Sentinel 5-P imagery to identify and quantify thousands of major methane plumes from various sources around the world. Thomas Lauvaux from the LSCE comments, “To date, only a handful of these large anthropogenic sources have been documented. To expand this, as Kayrros technology does, constitutes a significant step toward mitigating methane emissions around the globe, a significant contributor to climate change, with the support of operators who now have the required information to take immediate action.”

Antoine Rostand emphasizes, “The consequences of these findings are immense, as they enable individual companies in the energy sector to identify and address methane leaks across their networks. Equally, governments and regulators should take note that access to such detailed emissions data will drastically change their ability to hold emitters accountable and potentially reverse the trend of ever-increasing emissions rates.”

This technology is now available to the industry for immediate implementation.

About Kayrros

Kayrros is the leading global asset observation platform worldwide. Harnessing satellite imagery and unconventional data with machine learning, natural language processing and advanced mathematics, Kayrros delivers focused monitoring and measurement of energy and natural resource activity around the world. With access to data on more than 200,000 industry assets, Kayrros customers can observe individual or multiple assets in proprietary or multi-client workflows to analyse industrial and environmental performance for the insight needed to make optimal operational and financial decisions. For more information, please visit www.kayrros.com .

1

 

1 ton of methane is equivalent to 84 tons of CO2 in the first 20 years (Environment Defense Fund ).

2

 

Based on World bank Databank on CO2 emissions for 2014

3

 

Laboratoire des Sciences du Climat et de l’Environnement

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fujirebio Expands Access in Canada to Blood-based Neurology Testing with Health Canada Class II Medical Device Licenses for the Lumipulse® G NfL Blood and Lumipulse G pTau 217 Plasma Assays1.9.2026 07:00:00 CEST | Press release

H.U. Group Holdings Inc. and its wholly owned subsidiary Fujirebio today announced that Health Canada has issued Class II Medical Device Licenses (MDL) for the Lumipulse G NfL Blood and the Lumipulse G pTau 217 Plasma assay for use on the fully automated LUMIPULSE® G immunoassay platform in the Canadian market. "The approval of the Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays for clinical use in Canada marks another important step in our mission to expand access to reliable and clinically meaningful blood-based biomarkers for clinicians and patients worldwide," said Christiaan De Wilde, CEO of Fujirebio Europe N.V. “As a pioneer in neurological diagnostics, Fujirebio remains committed to advancing patient care through innovative, fully automated testing solutions." These approvals further strengthen Fujirebio’s comprehensive neurological diagnostics portfolio by broadening access to high-quality biomarker solutions designed to inform clinical decision-making across the

Helical Fusion Named a Final Candidate for Japan’s METI Fusion Power Demonstration Program1.9.2026 04:00:00 CEST | Press release

Milestone-based government program supports multiple fusion approaches toward power demonstration and commercialization Helical Fusion Co., Ltd., a fusion energy company developing a Helical Stellarator toward commercially viable fusion power, has been named a final candidate for Japan’s Ministry of Economy, Trade and Industry (METI) program supporting the demonstration of fusion power generation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831991676/en/ Image of Helix HARUKA, Helical Fusion’s Integrated Demo Device(left), and Helix KANATA, Helical Fusion’s Fusion Pilot Plant(right) The program is designed to accelerate fusion power demonstration in the 2030s under Japan’s national energy and fusion strategies. It supports private-sector technology development across multiple fusion approaches, including tokamak, stellarator and laser fusion, with approximately JPY 60 billion in total government support anticipated ove

Strategic Combination of ITC Infotech and Happiest Minds Technologies to Create a Scaled, Future-Ready, AI-First Global Technology Services Enterprise with US$ 1 Billion Revenue by FY28[1]31.8.2026 23:35:00 CEST | Press release

ITC Infotech Board approves proposed acquisition of 22.1% promoter stake and a Scheme of Amalgamation of the two companies ITC Infotech (ITCI), a wholly owned subsidiary of ITC Limited and a leading global technology services player, today announced the proposed strategic combination with Happiest Minds Technologies Limited (Happiest Minds) to create a scaled, future-ready, AI-first global technology services enterprise. The ITCI Board approved a proposal to acquire 22.1% equity stake from the promoter of Happiest Minds in two tranches under a Share Purchase Agreement. The transaction would be funded through a Rights Issue by ITC Infotech. ITCI Board has also approved a proposed Scheme of Amalgamation of Happiest Minds with ITCI which will be effected after the share acquisition. Pursuant to the scheme, the shares of ITCI will be listed on the stock exchanges. The proposed transaction has also been endorsed by the Board of Directors of ITC Limited. This strategic combination will syner

Angel’s Profits Grew Robustly in the First Half of 2026 with Europe and North America Turning Profitable Ahead of Schedule31.8.2026 21:07:00 CEST | Press release

Angelalign Technology Inc. (“Angel” or the “Company”) (6699.HK) (angelaligner.com), the second largest clear aligner supplier by revenue, announced today that its revenue grew 42.9% to US$230.7 million and net profit grew 79.6% to $25.5 million for the six months ending June 30, 2026. Angel’s business in Europe and North America crossed into profitability ahead of plan while the business in Chinese mainland delivered market share gains well above expectations. Doctors and staff in every region report that they are increasingly selecting Angel’s solutions after experiencing more predictable outcomes, especially on complex cases, and embracing the positive culture of the company. Dr. Mark Holt D.D.S., M.S. of Holt Orthodontics in Northern California, states: “We treat over half of our patients with clear aligners and our experience with Angel’s treatment plans and clear aligners has been tremendous.” “Our main focus is to provide great service to and being a rock-solid partner for our cu

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 21:00:00 CEST | Press release

Agreement advances patient access and strengthens BeOne's long-term commitment to U.S. innovation and manufacturing BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional res

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye